Who are tetracaine HCl and oxymetazoline HCL's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tetracaine-hcl-and-oxymetazoline-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

tetracaine HCl and oxymetazoline HCL — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tetracaine HCl and oxymetazoline HCL (tetracaine HCl and oxymetazoline HCL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with vasoconstrictor combination. Area: Otolaryngology / Surgery.

marketed Local anesthetic with vasoconstrictor combination Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline) Otolaryngology / Surgery Small molecule Live · refreshed every 30 min

Target snapshot

tetracaine HCl and oxymetazoline HCL (tetracaine HCl and oxymetazoline HCL) — Louisiana State University Health Sciences Center in New Orleans. This combination drug provides local anesthesia via tetracaine and nasal vasoconstriction via oxymetazoline to reduce bleeding and improve surgical visibility in nasal procedures.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tetracaine HCl and oxymetazoline HCL TARGET	tetracaine HCl and oxymetazoline HCL	Louisiana State University Health Sciences Center in New Orleans	marketed	Local anesthetic with vasoconstrictor combination	Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with vasoconstrictor combination class)

Louisiana State University Health Sciences Center in New Orleans · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tetracaine HCl and oxymetazoline HCL — Competitive Intelligence Brief. https://druglandscape.com/ci/tetracaine-hcl-and-oxymetazoline-hcl. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab